Portfolio company Vernal Biosciences, an innovative mRNA and LNP Contract Development and Manufacturing Organization (“CDMO”) announced the completion of a $20MM funding round, led by Ampersand Capital Partners and Charles River Labs with participation from Dynamk Capital and the Vermont Center for Emerging Technologies.

The company will use the funding to complete its first state of the art GMP manufacturing facility, scheduled to be online July 2023, and support expanded manufacturing and capabilities in support of cGMP manufacturing.